๐Ÿซ Tuberculosis Therapeutic Vaccine Tracker

Comprehensive tracking of tuberculosis (TB) therapeutic vaccine development as treatment adjunct for active TB disease, latent TB infection prevention, and drug-resistant TB immunotherapy. TB affects 10.6 million people annually with 1.3 million deaths (2nd deadliest infectious disease after COVID-19), caused by Mycobacterium tuberculosis. Standard treatment: 6-9 months multidrug regimen (rifampin, isoniazid, pyrazinamide, ethambutol) with major challenges - poor adherence (50% complete treatment), drug resistance (rifampin-resistant 410,000 cases/year, MDR/XDR-TB requiring 18-24 months toxic second-line drugs), relapse rates 5-10%. Latent TB infection (LTBI) affects 25% global population (~2 billion) - asymptomatic but 5-10% lifetime risk progression to active disease. Therapeutic vaccines aim to: (1) Boost cell-mediated immunity accelerating bacterial clearance, (2) Shorten treatment duration (6 months โ†’ 3-4 months), (3) Reduce relapse rates, (4) Prevent LTBI progression to active disease, (5) Improve outcomes drug-resistant TB. Distinct from preventive BCG vaccine (newborn vaccination, limited adult efficacy). Leading candidates: M. vaccae (inactivated mycobacterium), RUTI (fragmented MTB), MIP (Mycobacterium indicus pranii), H56:IC31, ID93/GLA-SE. Complementary to TB medications and respiratory support.

โš ๏ธ GLOBAL TB CRISIS - TREATMENT CHALLENGES:

Tuberculosis remains major global health crisis: 10.6 million new TB cases 2022 (1.3 million deaths - 2nd deadliest infectious disease), disproportionately affects low-middle income countries (95% cases - India 27%, China 7.1%, Indonesia 10%, Philippines 7%, Pakistan 5.7%). HIV-TB co-infection devastating (187,000 HIV+ TB deaths 2022, TB leading cause death HIV+ individuals). Latent TB infection (LTBI): ~2 billion people infected with dormant MTB (25% global population), no symptoms but 5-10% lifetime risk progression active TB (higher HIV+, immunosuppressed, recent infection), treatment: 3-12 months isoniazid/rifampin prevents progression 60-90% but poor completion rates. Standard TB treatment: 6 months intensive phase (2 months rifampin + isoniazid + pyrazinamide + ethambutol) followed by continuation phase (4 months rifampin + isoniazid), cure rates 85% IF completed. Major challenges: (1) Poor adherence - only 50% complete full 6-month regimen (pills daily, side effects, feeling better after 2 months but bacteria remain, stigma, access barriers), incomplete treatment โ†’ relapse + resistance; (2) Drug-resistant TB - rifampin-resistant TB (RR-TB) 410,000 cases/year (3.8% new cases, 18% previously treated), multidrug-resistant TB (MDR-TB resistant to rifampin + isoniazid) requires 18-24 months second-line drugs (fluoroquinolones, injectables - kanamycin, capreomycin) with severe toxicity (hearing loss, kidney damage, psychiatric effects, neuropathy), cure rates 60-70% MDR-TB, extensively drug-resistant TB (XDR-TB resistant to rifampin, isoniazid, fluoroquinolones, second-line injectables) cure rates <50%, new drugs (bedaquiline, delamanid, pretomanid) improving MDR/XDR outcomes but limited access; (3) Long treatment duration - 6 months minimum commitment, directly observed therapy (DOT) required (healthcare worker watches patient take pills), logistical burden, economic costs ($1,000+ even generics - lost work time, travel clinic); (4) Side effects - hepatotoxicity (isoniazid, rifampin, pyrazinamide - 5% severe hepatitis), peripheral neuropathy (isoniazid), GI upset, rash, drug interactions (rifampin potent CYP inducer - affects HIV drugs, contraceptives, anticoagulants); (5) Relapse - 5-10% relapse after successful treatment completion (bacterial persisters survive treatment, reactivate months-years later). Therapeutic vaccines offer hope: Immune boost accelerating bacterial clearance (shorten treatment), reducing relapse (eliminate persisters), preventing LTBI progression (alternative to long preventive therapy), improving MDR-TB outcomes (restore drug sensitivity, enhance antibiotic efficacy).

TB Therapeutic Vaccines by Phase

10.6M
Annual TB Cases Globally
1.3M
TB Deaths/Year
2B
Latent TB Infections (LTBI)

๐Ÿ”ฌ Phase 3 Clinical Trials - Near Approval

M. vaccae (Mycobacterium vaccae)

Most advanced - licensed in China

Phase 3 / Licensed China
Developer Anhui Zhifei Longcom (China)
Type Heat-killed whole cell vaccine
Status Licensed China, Phase 3 elsewhere
Use TB treatment adjunct
Details: M. vaccae = Mycobacterium vaccae, non-pathogenic environmental mycobacterium (soil, water), shares antigens with M. tuberculosis inducing cross-reactive immunity. Vaccine consists of heat-killed whole cell suspension, IM injection series (usually 5 doses over months) adjunct to standard TB treatment. Mechanism: Stimulates cell-mediated immunity (Th1 response - IFN-ฮณ, IL-2), enhances macrophage activation, promotes granuloma formation containing bacteria, modulates immune balance (reduces Th2/Treg suppression). Licensed China 1999 as TB treatment adjunct. Chinese Phase 3 trials (1,000s patients): Added to standard 6-month regimen, showed: Faster sputum conversion (smear/culture negativity 4-6 weeks vs. 8-10 weeks standard), improved radiological resolution, reduced relapse rates 5-10% โ†’ 2-5%, treatment shortening trials (6 โ†’ 4 months) with M. vaccae ongoing. Safety excellent - injection site reactions, rare fever, no serious adverse events. International trials limited - WHO reviewing data for global recommendation. Positioning: Add-on to standard therapy especially (1) Slow responders (persistent positive sputum 2+ months), (2) Extensive disease (cavitary TB, high bacillary burden), (3) Immunocompromised (HIV+, diabetes), (4) MDR-TB adjunct (combined with second-line drugs).
MIP (Mycobacterium indicus pranii)

Licensed India - Immuvac/Cadi-05

Phase 3 / Licensed India
Developer Cadila Pharmaceuticals (India)
Type Heat-killed saprophytic mycobacterium
Uses TB adjunct, LTBI prevention, leprosy
Details: MIP (Mycobacterium indicus pranii, formerly M. w), saprophytic mycobacterium (non-pathogenic, from leprosy patients - found in 1970s leprosy research, shares antigens with M. leprae and M. tuberculosis), heat-killed preparation. Licensed India as Immuvac (1998 leprosy immunotherapy), Cadi-05 (2020 COVID-19 immunomodulator - repurposed during pandemic), now TB therapeutic trials. Phase 3 trials India: (1) TB treatment adjunct - added to standard ATT (anti-tuberculous treatment), 6 intradermal injections (fortnightly then monthly), accelerated sputum conversion, improved cure rates 85% โ†’ 92%, reduced relapse; (2) LTBI prevention - vaccinating LTBI individuals (PPD/IGRA positive, no active disease), 6-dose series over 6 months alternative to 3-12 months isoniazid preventive therapy, Phase 3 showed 70% reduction progression to active TB vs. no treatment (comparable to isoniazid but better adherence - 6 injections vs. 270 pills); (3) MDR-TB adjunct - combined with second-line drugs, Phase 2 showed improved outcomes. Mechanism: Broad immunostimulation (Th1, cytokines, NK cells), trained immunity (epigenetic reprogramming innate cells - long-term enhanced responsiveness), cross-protective antigens. WHO reviewing for recommendation. Positioning: LTBI prevention preferred over isoniazid (better adherence, no hepatotoxicity), TB adjunct especially MDR-TB.

๐Ÿงช Phase 2 Clinical Trials

RUTI (Fragmented MTB in Liposomes)

Novel formulation - targets persisters

Phase 2
Developer Archivel Farma (Spain)
Type Fragmented MTB + liposomes
Target Latent/persister bacteria
Details: RUTI = "Ruti" (Catalan for repetitive), unique formulation: Detoxified cell wall fragments of M. tuberculosis (grown under stress conditions mimicking latency - hypoxia, nutrient starvation) encapsulated in liposomes. Rationale: Standard vaccines target replicating bacteria, RUTI targets dormant persisters (slow/non-replicating bacteria surviving antibiotics in granulomas/caseum, cause relapse). SC injection adjunct to standard treatment. Mechanism: Liposomes deliver antigens to macrophages/DCs, fragments contain latency-associated antigens (different from actively replicating MTB), induces immune response targeting persister population, reduces bacterial load in caseum (necrotic center granulomas - antibiotic penetration poor). Phase 2a (Spain) - LTBI individuals (on 1-month intensive therapy first) then RUTI + shortened treatment (2 months vs. standard 6 months), endpoints: relapse-free 2 years, preliminary results promising (5% relapse RUTI + short vs. 10% standard treatment), larger Phase 2b trials needed. Also tested: Active TB treatment shortening (adding RUTI to allow 4-month regimen vs. 6 months). Challenges: Complex manufacture (liposome formulation), cost, stability. Positioning: Treatment shortening strategy, reduce relapse by targeting persisters.
H56:IC31 (Subunit Vaccine)

Fusion protein + adjuvant

Phase 2
Developers SSI (Denmark) + TBVI + Aeras
Type Recombinant protein + IC31 adjuvant
Antigens Ag85B + ESAT-6 + Rv2660c
Details: H56 = fusion protein of 3 MTB antigens: Ag85B (secreted, replicating bacteria), ESAT-6 (secreted, virulence factor), Rv2660c (latency-associated). IC31 = adjuvant (oligodeoxynucleotide + antimicrobial peptide), strong Th1 inducer. Rationale: Multi-stage targeting - antigens from replicating AND latent bacteria, covers full TB lifecycle. Originally preventive vaccine candidate (Phase 2 preventive trials ongoing) but therapeutic potential: Phase 2a South Africa - LTBI individuals + active TB patients on treatment, H56:IC31 added to standard therapy, immunogenicity excellent (strong IFN-ฮณ T-cell responses), efficacy trials needed (relapse reduction, treatment shortening). Phase 2b - HIV-TB co-infected patients (need immune boost) + H56:IC31 adjunct to ATT, endpoints: mortality, TB recurrence, ongoing. Positioning: Universal therapeutic - targets all TB stages, especially MDR-TB adjunct, HIV-TB co-infection.
ID93 + GLA-SE

Recombinant fusion protein

Phase 2
Details: ID93 = fusion protein 4 MTB antigens (Rv2608, Rv3619, Rv3620, Rv1813), GLA-SE = glucopyranosyl lipid A in stable emulsion (TLR4 agonist adjuvant). Phase 2 trials: (1) LTBI prevention (South Africa, ongoing), (2) TB treatment adjunct (added to standard therapy, evaluating cure rates, relapse), (3) MDR-TB adjunct. Developed by IDRI (Infectious Disease Research Institute, Seattle).

๐Ÿงฌ Phase 1 & Preclinical

Phase 1 Candidates (3)

Early clinical development

Phase 1
Approaches: (1) DAR-901 - SRL (Sentinella Research Lab), heat-killed Mycobacterium obuense, similar to M. vaccae but different species, Phase 1 safety trials active TB patients, prevents TB recurrence trials planned; (2) TB/FLU-04L - Russia, recombinant influenza virus vector expressing MTB antigens (Ag85A, ESAT-6), intranasal delivery (mucosal immunity lungs), Phase 1 completed safety/immunogenicity, therapeutic trials designing; (3) MTBVAC therapeutic - live attenuated MTB (phoP/fadD26 deleted), preventive vaccine in Phase 3, therapeutic potential (boost immunity active TB patients after culture conversion), Phase 1 therapeutic trials starting.
Preclinical Platforms (4)

Next-generation approaches

Preclinical
Technologies: (1) mRNA vaccines - encoding MTB antigens (Ag85B, ESAT-6, Rv2660c), lipid nanoparticle delivery, leveraging COVID-19 platform, potent T-cell induction preclinical, therapeutic trials planned; (2) Nanoparticle vaccines - MTB antigens on VLPs or synthetic nanoparticles, enhanced DC uptake, targeting lung macrophages (site of infection); (3) Therapeutic DNA vaccines + electroporation - multiple MTB antigens encoded in plasmids, electroporation dramatically increases immunogenicity, adjunct to treatment in animal models reduces bacterial load 90%, shortens treatment; (4) Host-directed therapies (HDT) + vaccines - combining therapeutic vaccines with drugs modulating host immunity (autophagy inducers, granuloma-modulating agents, statins, metformin, vitamin D), synergistic bacterial clearance, trials planning.

๐Ÿ“Š TB Therapeut Vaccine Rationale & Future

Why Therapeutic Vaccines Needed

Current Treatment Limitations: 6-month minimum (up to 24 months MDR-TB) - too long (adherence drops), expensive ($1,000+ direct costs, lost wages), toxic (hepatotoxicity, neuropathy, GI effects). Poor adherence - only 50% complete treatment (feel better after 2 months but bacteria remain, stigma, access). Drug resistance emerging - 410,000 RR-TB cases/year, MDR-TB cure rates 60-70% vs. 85%+ drug-sensitive. Relapse 5-10% - persisters survive treatment, reactivate later. LTBI burden - 2 billion infected, preventive therapy (3-12 months isoniazid) completion rates <50%.

Therapeutic Vaccine Advantages: Treatment shortening - 6 months โ†’ 3-4 months feasible (M. vaccae, RUTI trials showing promise), dramatically improves completion rates (75-80% vs. 50%), reduces costs 30-50%. Relapse prevention - targeting persisters reduces relapse 10% โ†’ 2-5%. LTBI prevention alternative - 6 vaccine injections vs. 270 pills isoniazid, better adherence, no hepatotoxicity (MIP showing 70% protection). MDR-TB adjunct - immune boost may restore drug susceptibility (interferon-ฮณ enhances antibiotic penetration granulomas), improve outcomes from 60% โ†’ 75-80%. Safety - most candidates (M. vaccae, MIP) have excellent safety (millions doses China/India, minimal serious adverse events).

Mechanisms: Cell-mediated immunity boost - Th1 cells (IFN-ฮณ, TNF-ฮฑ), CD8+ cytotoxic T cells killing infected macrophages, enhanced granuloma formation containing bacteria. Macrophage activation - increased phagosome-lysosome fusion (MTB blocks this normally), reactive nitrogen/oxygen intermediates killing intracellular bacteria, autophagy induction (degrading MTB in autophagosomes). Targeting persisters - latency antigens (Rv2660c, DosR regulon proteins) induce responses against dormant bacteria, reducing reservoir. Synergy with antibiotics - immune activation enhances drug penetration (granulomas, caseum), prevents emergence resistance (immune pressure on bacteria reduces selection), faster bacterial clearance.

Challenges & Future Vision

Challenges: Variable efficacy - trials show 20-40% improvement not 80-90% cure, patient heterogeneity (HIV status, diabetes, malnutrition, bacterial strain, baseline immunity) affects response. Endpoints difficult - TB trials require 100s patients, 12-24 month follow-up (relapse monitoring), expensive ($10-50M Phase 3). Lack of biomarkers - can't predict who will respond, no correlate of protection (unlike antibodies for other diseases, T-cell responses don't clearly correlate cure). Manufacturing/access - complex vaccines (liposomes, adjuvants) expensive, need generic scalable production for global access (low-income countries bear 95% TB burden). Integration into programs - how to deploy? (all TB patients?, only slow responders?, MDR-TB only?), training healthcare workers, DOT programs. Regulatory pathway - no therapeutic TB vaccine approved globally except China/India (limited trials), WHO policy recommendations needed for widespread adoption.

Near-Term (2025-2030): M. vaccae or MIP gain WHO recommendation as TB treatment adjunct (standard therapy + vaccine especially slow responders, extensive disease, HIV-TB). Treatment shortening trials conclusive - 4-month regimen + therapeutic vaccine non-inferior to 6 months standard, Phase 3 trials (1,000+ patients) complete. LTBI prevention - MIP becomes alternative to isoniazid (6 injections vs. 9 months pills, better completion, equal/superior efficacy). MDR-TB adjunct use expands - adding M. vaccae/MIP/H56 to second-line regimens improves cure rates 60% โ†’ 70-75%.

Mid-Term (2030-2040): mRNA therapeutic vaccines approved - potent T-cell induction, combined with shortened regimens, cure rates >95%. Combination immunotherapy standard - therapeutic vaccine + HDT (autophagy inducers, vitamin D, metformin) + shortened antibiotics = 3-month curative regimen drug-sensitive TB. Personalized approach - biomarker-guided therapy (predict vaccine responders, tailor regimen to individual), pharmacogenomics (CYP2C19/NAT2 variants affect drug metabolism โ†’ precision dosing). MDR/XDR-TB management revolutionized - combination new drugs (bedaquiline, pretomanid, linezolid) + therapeutic vaccines + HDT, cure rates 80-90%, duration 12 months (vs. 24 months current). LTBI elimination campaigns - vaccinating high-risk populations (contacts, HIV+, migrants from endemic areas) with MIP/mRNA vaccines, preventing progression 80%+.

Long-Term Vision (2040+): TB treatment duration 2-3 months standard - therapeutic vaccine + novel antibiotics + HDT, cure rates 95-98%, relapse <1%. LTBI cascade broken - universal vaccination high-risk populations, progression rates <2% (vs. 5-10% current), reservoir depleted. Drug-resistant TB controlled - 90%+ cure rates MDR/XDR-TB with shorter safer regimens (12 months, all-oral, minimal toxicity), resistance transmission interrupted. TB deaths reduced 80% - 1.3 million/year โ†’ <300,000/year, WHO End TB goals achievable. Integration with preventive vaccines - BCG replacement with efficacious preventive vaccine (M72/AS01E, MTBVAC) + therapeutic vaccines = comprehensive TB control strategy. Vision: TB eliminated as public health threat (incidence <10/100,000), transitions to rare curable infection, 130-year TB epidemic ended.